Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy

  • Cancer is the second leading cause of death worldwide, with nearly 10 million deaths annually.1, 2 In the U.S., approximately 1.9 million new cancer cases are expected to be diagnosed in 2021.1
  • Based on cancer biomarkers, the first-of-its-kind VENTANA MMR RxDx Panel helps determine which solid tumour patients may benefit from GSK immunotherapy.
  • Roche/GSK collaboration represents an important step towards a personalised healthcare strategy for certain solid tumour patients.

Continue reading

BIO builds on BIOEquality Efforts with New LinkdIn Group

In 2020,  BIO launched the BIOEquality Agenda, a national effort in collaboration with our partners in the biotechnology sector and BIO members that aims to counteract the systemic inequality, injustice, and unfair treatment of underserved communities.

Today, as part of the BIOEquality Agenda, Dr. Michelle McMurry-Heath, president & CEO of BIO,  announced the launch of BIO’s new LinkedIn group, Forum for Diversity in Biotech and STEM to connect BIO members with diverse, talented, and industry-trained individuals. This group will be instrumental in helping our industry invest in the current and next generation of underrepresented scientists and make our entire sector stronger.
Continue reading

Startup with an Innovative Imaging System Wins Sponsorship at The University of Arizona Center for Innovation Fueled by Concord General Contracting

TUCSON, Ariz.– The University of Arizona Center for Innovation (UACI) is pleased to announce that QScint Imaging Solutions, LLC. has won the UACI Sponsored Launch Fueled by Concord General Contracting competition.

QScint Imaging Solutions, LLC. manufactures iQID charged-particle digital autoradiography imaging systems for use in radiopharmaceutical drug development, geological studies, and nuclear forensics applications.

Continue reading

The NSF Awards ZelosDx $255,000 For the Development of WINDOW INTO THE BRAIN Biomarker Technology

TUCSON, AZ, July 27, 2021 – ZelosDx, Inc. announced today that the company is the recipient of a Small Business Innovation Research (SBIR) Phase l Award from the National Science Foundation (NSF) for a grant entitled, “ Phagocytic Cells in Peripheral Blood as a Novel Diagnostic Tool for Brain Health”. The company will receive a one-year grant of up to $255,000 to expand the company’s pioneering biomarker research.Continue reading